IPthinktank
IP ThinkTank blogIP Scorecards

back to scorecards index

Browse Scorecards

Click here to receive Global IP Scorecards™ by email

CONTACTSUBSCRIBE

Gleevec / Glivec (Imatinib)

Contribute to this scorecard

Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It was originally coded during development as CGP57148B or STI-571 (these terms are used in early preclinical publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

Copyright Thursday, January 17, 2008 Duncan Bucknell

Updates by Country

   (Click on a country name to view)